Lilly reveals that an Inluriyo/Verzenio combo is being limited to ESR1-mutant disease.
ApexOnco Front Page
Recent articles
Arcus steps back from TIGIT as its Fc-silent claim crumbles.
Studies presented at ASH show this to be true only up to a point.
Linker-MM4 data raise more questions about sequencing of therapies for multiple myeloma.
Pfizer reveals the discontinuation of PF-08046044.
Tecvayli plus Darzalex could challenge Carvykti in the push for a functional cure.
The company might have blown Enliven out of the water.
The company will try to get the Komzifti QTc prolongation warning removed.
